COMMITMENTS AND CONTINGENCIES (Details Narrative) |
6 Months Ended | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
|
Oct. 04, 2023
USD ($)
|
Feb. 02, 2023
USD ($)
|
Jun. 30, 2026
USD ($)
$ / shares
shares
|
Jun. 30, 2026
EUR (€)
shares
|
Dec. 31, 2025
USD ($)
|
Mar. 11, 2025
USD ($)
|
Mar. 04, 2025
USD ($)
|
Jan. 05, 2024
USD ($)
|
Sep. 30, 2019
USD ($)
|
Dec. 10, 2015
USD ($)
|
|
| Cash received | $ 21,237 | $ 139,360 | ||||||||
| Compensation for services, description | As of May 14, 2021, the Company has entered into four consulting agreements. In compensation for services: (i) one consultant shall receive a remuneration amount of $10,000-$12,500 per month and has earned 1% of the Company’s majority owned subsidiary, BioCorRx Pharmaceuticals as of May 7, 2021 based on FDA clearance of Company’s IND application; consulting agreement terminated in April 2021 (ii) one consultant shall receive common stock equivalent to $1,375 on the last day of each month; (iii) two consultants shall receive common stock equivalent to $3,750 on the last day of each month; and (iv) one consultant shall receive a remuneration amount of $3,500 per month. | As of May 14, 2021, the Company has entered into four consulting agreements. In compensation for services: (i) one consultant shall receive a remuneration amount of $10,000-$12,500 per month and has earned 1% of the Company’s majority owned subsidiary, BioCorRx Pharmaceuticals as of May 7, 2021 based on FDA clearance of Company’s IND application; consulting agreement terminated in April 2021 (ii) one consultant shall receive common stock equivalent to $1,375 on the last day of each month; (iii) two consultants shall receive common stock equivalent to $3,750 on the last day of each month; and (iv) one consultant shall receive a remuneration amount of $3,500 per month. | ||||||||
| Total consideration amount | $ 743,971 | |||||||||
| Accounts receivables | 67,694 | 253,459 | ||||||||
| Charles River Laboratories, Inc. [Member] | ||||||||||
| Outstanding debt balance | $ 28,936 | |||||||||
| BICX Holding Company LLC [Member] | ||||||||||
| Common stock issued upon convertible debt | shares | 2,227,575 | 2,227,575 | ||||||||
| Convertible Promissory Note | $ 4,160,000 | |||||||||
| Total Interest Payment | $ 1,138,157 | |||||||||
| Issuance price per share | $ / shares | $ 2.00 | |||||||||
| Conversion agreement description | the Company’s financial statements as an amount due and owing to the Investor to be repaid within twelve (12) months of the closing of the Public Offering, or if the Public Offering is terminated or abandoned | the Company’s financial statements as an amount due and owing to the Investor to be repaid within twelve (12) months of the closing of the Public Offering, or if the Public Offering is terminated or abandoned | ||||||||
| Orange County Research Center [Member] | ||||||||||
| Payment of clinical services | $ 503,089 | |||||||||
| Pellecome [Member] | ||||||||||
| Total cost and attorney's fees payment | 235,886 | |||||||||
| Attorney's fees received or awarded | $ 222,933 | $ 222,933 | ||||||||
| Settelment amount | $ 418,000 | |||||||||
| Outstanding debt balance | $ 16,500 | |||||||||
| Interest rate | 10.00% | 10.00% | ||||||||
| Remaining commitment | $ 198,000 | |||||||||
| Pellecome [Member] | January 5, 2024 [Member] | ||||||||||
| Attorney's fees awarded | 332,503 | |||||||||
| Accrued interest | $ 94,816 | |||||||||
| Consultant [Member] | ||||||||||
| Advisory services agreement description | the Company is required to pay a monthly retainer fee of EUR 4,000 for the initial six-month period, consisting of EUR 2,000 payable in cash and EUR 2,000 payable in shares of the Company’s common stock | the Company is required to pay a monthly retainer fee of EUR 4,000 for the initial six-month period, consisting of EUR 2,000 payable in cash and EUR 2,000 payable in shares of the Company’s common stock | ||||||||
| Common share issued for services | shares | 3,000 | 3,000 | ||||||||
| Renumeration amount | $ 1,417 | |||||||||
| Monthly retainer fee converted | € | € 4,000 | |||||||||
| Alpine Creek [Member] | ||||||||||
| Royalty amount due | 91 | 91 | ||||||||
| Total consideration amount | 1,531,926 | $ 1,531,926 | ||||||||
| Accounts receivables | $ 1,215,000 | |||||||||
| Payment received for services | $ 1,620,000 | |||||||||
| Payable commitment description | On any other proprietary implant distribution, that excludes the “treatment”, for alcohol and opioid addiction and for which no other payment is due, the Company shall pay 2.5% of the Company’s gross profit for implant distribution not to exceed $100 per sale | On any other proprietary implant distribution, that excludes the “treatment”, for alcohol and opioid addiction and for which no other payment is due, the Company shall pay 2.5% of the Company’s gross profit for implant distribution not to exceed $100 per sale | ||||||||
| Payable per treatment sold | $ 100 | |||||||||
| Profit holding percentage | 50.00% | |||||||||
| Board of directors | ||||||||||
| Annual compensation | $ 200,000 | |||||||||
| Cash received | $ 15,000 | |||||||||
| Stock equivalent amount | $ 5,000 | |||||||||